Ilsa M. Coleman
YOU?
Author Swipe
View article: Moving Beyond Binary Biomarkers: Machine Learning Model Resolves Concurrent and Molecularly Heterogeneous Mismatch Repair and Homologous Recombination Deficiencies in Prostate Cancer
Moving Beyond Binary Biomarkers: Machine Learning Model Resolves Concurrent and Molecularly Heterogeneous Mismatch Repair and Homologous Recombination Deficiencies in Prostate Cancer Open
Current DNA damage repair (DDR) biomarkers employ binary classifications that fail to capture the molecular complexity of tumors with concurrent repair deficiencies. We used genomics analysis to stratify 672 metastatic prostate cancer pati…
View article: Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology
Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology Open
A cornerstone of research to improve cancer outcomes involves studies of model systems to identify causal drivers of oncogenesis, understand mechanisms leading to metastases, and develop new therapeutics. Although most cancer types are rep…
View article: Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer
Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer Open
Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive subtype of prostate cancer (PC) without curative treatments. Antibody-drug conjugates (ADCs) emerged as promising cancer therapeutics that selectively deliver cytotox…
View article: Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
Supplemental figure 1
View article: Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
Estimated probabilities of HER2 expression conditional on an index sample
View article: Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
Supplemental figure 2
View article: Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
UC cohort supplemental table
View article: Data from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Data from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the land…
View article: Figure 3 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure 3 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in (A) prostate cancer and (B) urothelial cancer.
View article: Figure 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
A and B, Representative micrographs of HER2 IHC staining in prostate cancer (A) and urothelial cancer (B) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Nu…
View article: Supplementary Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Supplementary Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
Prostate cancer cohort supplemental table
View article: Figure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
A and B, Mosaic plots indicating the relationship between ERBB2 genomic status as assessed by unadjusted copy number and HER2 IHC in (A) prostate and (B) urothelial cancers. C and D, Box plots indicating the relationship between HER2 RNA e…
View article: Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the land…
View article: Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer Open
Metastatic prostate cancer (mPC) is a clinically and molecularly heterogeneous disease. While there is increasing recognition of diverse tumor phenotypes across patients, less is known about the molecular and phenotypic heterogeneity prese…
View article: Figure 5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800-resistant 22Rv1 prostate cancer cell sublines demonstrate the reversal of the NXP800-mediated phenotype. A, Long-term treatment of 22Rv1 prostate cancer cells with increasing concentrations (up to 2.5 μmol/L) of DMSO (vehicle-C, whi…
View article: Figure 1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
GO cellular response to heat gene expression signature associates with AR signaling and poorer prognosis in men suffering from CRPC. A and G, Two independent (PCF-SU2C and ICR-RMH) transcriptome cohorts of patients with CRPC. Quantificatio…
View article: Figure 3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800 inhibits the growth of AR-dependent and AR-independent prostate cancer models with activation of the UPR and inhibition of key signaling pathways. A and B, PDX-O [CP50, CP89, CP129, and CP142 (A)], AR-positive (VCaP, LNCaP, LNCaP95,…
View article: Figure 2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800 inhibits AR transactivation and AR signaling to inhibit the growth of AR aberrant prostate cancer models. A–C, VCaP (A), LNCaP95 (B), and 22Rv1 (C) prostate cancer cells were treated with vehicle (DMSO 0.1%) or various concentration…
View article: Supplementary Figure S6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 6: Inhibition of the unfolded protein response with ISRIB rescues NXP800-mediated suppression of AR signaling and PCa model growth
View article: Supplementary Figure S2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 2: AR and AR-V7 bind members of the 70KDa heat shock protein family and heat shock mediated cellular stress increases HSP72 and AR-V7 protein expression, and associates with GO Cellular Response to Heat gene expression…
View article: Figure 6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800 activates the UPR and inhibits E2F-mediated transcription to drive antitumor activity against the castration-resistant VCaP prostate cancer cell line–derived mouse xenograft. A and B, Castration-resistant emergent VCaP prostate canc…
View article: Supplementary Figure S4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 4: NXP800 decreases basal HSP72 protein levels and blocks HSP72 protein induction in response to HSP90 inhibition in PCa cell lines
View article: Supplementary Figure S10 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S10 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 10: NXP800 demonstrates limited impact on AR and AR-V7 protein levels and associated AR signaling in-vivo but does induce apoptosis and reduce cellular proliferation
View article: Supplementary Figure S8 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S8 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 8: NXP800 does not further impact AR transactivation or AR signaling in NXP800-resistant 22Rv1 PCa cell sub-lines.
View article: Supplementary Figure S5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 5: Enzalutamide inhibits AR signaling in enzalutamide responsive VCaP PCa cells but not enzalutamide resistant LNCaP95 and 22Rv1 PCa cells.
View article: Supplementary Figure S3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 3: GO Cellular Response to Heat gene expression signature associates with AR signaling in CRPC transcriptomes
View article: Data from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Data from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Purpose:Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men with advanced prostate cancer, but treatment resistance …
View article: Supplementary Tables S1-S13 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Tables S1-S13 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary Tables
View article: Supplementary Figure S9 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S9 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 9: NXP800 demonstrates tolerability in a castration-resistant VCaP PCa cell line-derived mouse xenograft